Recombinant Ralstonia eutropha capable of producing polylactic acid or polylatic acid polymer, and method for producing polylactic acid or polylatic acid copolymer using same

ABSTRACT

Provided are a recombinant  Ralstonia eutropha  capable of producing polylactate or a hydroxyalkanoate-lactate copolymer, and a method of preparing polylactate or a hydroxyalkanoate-lactate copolymer using the same. The recombinant  Ralstonia eutropha , which is prepared by introducing a gene of an enzyme converting lactate into lactyl-CoA and a gene of a polyhydroxyalkanoate (PHA) synthase using lactyl-CoA as a substrate thereto, may be cultured, thereby efficiently preparing a lactate polymer and a lactate copolymer.

This application is a continuation of U.S. application Ser. No.14/133,082, filed Dec. 18, 2013, which is a continuation application ofU.S. application Ser. No. 13/147,572, filed Aug. 2, 2011, now U.S. Pat.No. 8,685,701, which is a National Stage Entry of InternationalApplication No. PCT/KR2010/000653, filed on Feb. 3, 2010, and claimspriority to Korean Patent Application No. 10-2009-0009256 filed Feb. 5,2009, all of which are hereby incorporated by reference in theirentirety as if fully set forth herein.

TECHNICAL FIELD

The present invention relates to a recombinant Ralstonia eutrophacapable of producing polylactate or a hydroxyalkanoate-lactate copolymerand a method of preparing polylactate or a hydroxyalkanoate-lactatecopolymer using the same.

BACKGROUND ART

Polylactate (PLA) is a common biodegradable polymer derived from lactatethat is highly applicable to the synthesis of general-purpose or medicalpolymers. Today, polymerization of lactates produced by microbialfermentation is a method for synthesizing PLA. However, this directpolymerization of lactates can only produce PLA with low molecularweight (1000 to 5000 daltons). PLA with a molecular weight of 100,000daltons or more may be polymerized from smaller PLA molecules producedby the direct polymerization of lactates using a chain coupling agent.However, this method adds some complications to the process due to theaddition of a solvent or chain coupling agent, both of which aredifficult to remove. The most widely used method of producing highmolecular weight PLA includes the conversion of lactate into lactide aswell as the synthesis of PLA using the ring-opening polyaddition oflactide rings.

When PLA is synthesized from lactate, producing a PLA homopolymer iseasy. However, it is difficult to synthesize PLA copolymers that havevarious compositions of monomers and very ineffective in a commercialaspect.

Polyhydroxyalkanoate (PHA) is polyester that acts as an energy or carbonstorage molecule in microorganisms when there are excessive levels ofcarbon but a lack of other nutrients such as phosphorus, nitrogen,magnesium and oxygen. PHA is known as an alternative to conventionalsynthetic plastic due to its similarity to conventional syntheticpolymer derived from petroleum as well as its perfect biodegradability.

To produce PHA from microorganisms, there must be present an enzyme thatconverts the metabolic product of the microorganism into PHA monomer aswell as PHA synthase, which then synthesizes PHA polymer from PHAmonomers. To synthesize PLA and PLA copolymer using microorganisms, asystem as described above is needed, as well as enzymes capable ofproviding lactyl-CoA and hydroxyacyl-CoA, which is originally asubstrate for PHA synthase.

Further, for economical production of biodegradable polymer, it iscrucial to efficiently accumulate PLA and PLA copolymer in the cell. Inparticular, it is necessary to produce a high concentration of PLA andPLA copolymer through high concentration cultivation. Thus, technologythat allows the efficient production of a recombinant microorganismcompatible with the conditions described above is needed.

DISCLOSURE Technical Problem

The objective of the present invention is the development of arecombinant Ralstonia eutropha (R. eutropha) capable of producing ahigh-concentration polylactate or hydroxyalkanoate-lactate copolymer anda method of preparing polylactate or a hydroxyalkanoate-lactatecopolymer using the same.

Technical Solution

One aspect of the present invention is a recombinant strain of R.eutropha capable of producing a high concentration of polylactatepolymer or copolymer as well as a method of preparing polylactate orhydroxyalkanoate-lactate copolymer using said strain.

The inventors succeeded in synthesizing polylactate polymer andcopolymer using propionyl-CoA transferase derived from Clostridiumpropionicum (C. propionicum) that produces lactyl-CoA as well as aPseudomonas sp. 6-19-derived mutant of polyhydroxyalkanoate synthasethat uses the newly synthesized lactyl-CoA as a substrate (Korean PatentApplication No. 10-2006-0116234).

Furthermore, the inventors intended to prepare a recombinant strain ofR. eutropha capable of efficiently producing polylactate polymer for theeconomical production of a biodegradable polymer. To this end, theinventors prepared a recombinant R. eutropha having lost PHA productioncapability, and a transformed recombinant R. eutropha by transformingthe recombinant R. eutropha with a plasmid expressing propionyl-CoAtransferase derived from C. propionicum and a polyhydroxyalkanoatesynthase of Pseudomonas. sp. 6-19 or introducing a gene expressing apropionyl-CoA transferase derived from C. propionicum and a geneexpressing a polyhydroxyalkanoate synthase of P. sp. 6-19 to arecombinant R. eutropha having lost PHA production capability. Theinventors found that polylactate polymer and copolymer could beefficiently prepared from glucose using the recombinant R. eutropha asprepared above. This entails the present invention.

Advantageous Effects

The present invention includes a recombinant strain of Ralstoniaeutropha (R. eutropha) capable of efficiently producing polylactate orhydroxyalkanoate-lactate copolymer as well as a method of preparingpolylactate or hydroxyalkanoate-lactate copolymer by culturing this samestrain.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 and 2 illustrate the process of preparing a recombinantexpression vector containing the mutant gene of polyhydroxyalkanoatesynthase derived from Pseudomonas sp. 6-19, the mutant gene ofpropionyl-CoA transferase derived from C. propionicum, and a phaAB genederived from R. eutropha.

FIG. 3 illustrates a process of mating between Escherichia coli 517-1and R. eutropha as well as the insertion of a target gene into thechromosome of R. eutropha to prepare recombinant R. eutropha.

MODE FOR INVENTION

The present invention provides a recombinant strain of R. eutropha thatcan produce polylactate or a hydroxyalkanoate-lactate copolymer, suchthat the polyhydroxyalkanoate (PHA) biosynthesis gene operon ofwild-type Ralstonia eutropha is removed and the gene of the enzymeconverting foreign lactate to lactyl-CoA along with the gene of PHAsynthase whose substrate is lactyl-CoA is introduced.

In the present invention, the gene of the enzyme converting lactate tolactyl-CoA may be that of propionyl-CoA transferase (pct).

In one particular embodiment, the pct gene can be derived from C.propionicum.

In the present invention, the pct gene may be a mutant form that encodespropionyl-CoA transferase with equal or superior lactyl-CoA producingactivity.

In one particular embodiment, the pct gene may have the followingnucleotide sequences: the nucleotide sequence (cp-pct) of SEQ ID NO: 1;the nucleotide sequence (cppct512) of SEQ ID NO: 1 containing the A1200Gmutation; the nucleotide sequence (cppct522) of SEQ ID NO: 1 containingthe T78C, T669C, A1125G, and T1158C mutations; the nucleotide sequence(cppct531) of SEQ ID NO: 1 containing the A1200G mutation whosecorresponding amino acid sequence contains the Gly335Asp mutation; thenucleotide sequence (cppct532) of SEQ ID NO: 1 containing the A1200Gmutation whose corresponding amino acid sequence contains the Ala243Thrmutation; the nucleotide sequence (cppct533) of SEQ ID NO: 1 containingthe T669C, A1125G, and T1158C mutations whose corresponding amino acidsequence contains the Asp65Gly mutation; the nucleotide sequence(cppct534) of SEQ ID NO: 1 containing the A1200G mutation whosecorresponding amino acid sequence contains the i Asp257Asn mutation; thenucleotide sequence (cppct535) of SEQ ID NO: 1 containing the T669C,A1125G, and T1158C mutations whose corresponding amino acid sequencecontains the Asp65Asn mutations; the nucleotide sequence (cppct537) ofSEQ ID NO: 1 containing the T669C, A1125G, and T1158C mutations whosecorresponding amino acid sequence contains the Thr199Ile mutation; andthe nucleotide sequence (cppct540) of SEQ ID NO: 1 containing the T78C,T669C, A1125G, and T1158C mutations whose corresponding amino acidsequence contains the Val193Ala mutation.

The pct gene mutants may be prepared by the method disclosed in KoreanPatent Application No. 10-2007-0081855. In one particular embodiment,the pct gene preferably have the nucleotide sequence (cppct540) of SEQID NO: 1 containing the T78C, T669C, A1125G, and T1158C mutations whosecorresponding amino acid sequence contains the Val193Ala mutation.

Meanwhile, in the present invention, the gene of PHA synthase usinglactyl-CoA as its substrate may be the PHA synthase gene of Pseudomonassp. 6-19.

In the present invention, the gene of PHA synthase using lactyl-CoA asits substrate includes a mutant thereof that encodes PHA synthase havingequal or superior PHA synthesizing capability.

In one particular embodiment, the gene of PHA synthase using lactyl-CoAas its substrate may possess, but is not limited to, a nucleotidesequence corresponding to the amino acid sequence of SEQ ID NO: 2 or theamino acid sequence of SEQ ID NO: 2 with at least one of the followingmutations: E130D, S325T, L412M, S477R, S477H, S477F, S477Y, S477G,Q481M, Q481K and Q481R.

Mutation of the gene encoding PHA synthase using lactyl-CoA as itssubstrate may be performed by the method disclosed in Korean PatentApplication No. 10-2008-0068607. In one particular embodiment, the PHAsynthase gene have the nucleotide sequence corresponding to at least oneamino acid sequence selected from the group consisting of: the aminoacid sequence (C1335) of SEQ ID NO: 2 containing the E130D, S325T,L412M, S477G and Q481M mutations; the amino acid sequence (C1310) of SEQID NO: 2 containing the E130D, S477F and Q481K mutations; and the aminoacid sequence (C1312) of SEQ ID NO: 2 containing the E130D, S477F andQ481R mutations.

In the present invention, the recombinant strain of R. eutropha mayfurther include a gene coding 3HB-CoA synthase. The gene encoding3HB-CoA synthase allows the preparation of hydroxyalkanoate-lactatecopolymer with a high molar fraction of hydroxyalkanoate, even whenhydroxyalkanoate is not present in the medium.

In one particular embodiment, the gene coding 3HB-CoA synthase mayinclude a ketothiolase gene and acetoacetyl-CoA reductase gene, both ofwhich may be derived from, but not limited to R. eutropha. In thepresent invention, recombinant R. eutropha may furthermore include aPhaG gene.

In one particular embodiment, the PhaG gene may be derived from P.Putida KT2440. When the PhaG gene is also included in recombinant R.eutropha, recombinant R. eutropha becomes capable of producing ahydroxyalkanoate-lactate copolymer of MCL.

Introduction of the gene encoding the enzyme that converts lactate tolactyl-CoA, the gene of PHA synthase that uses lactyl CoA as asubstrate, the gene encoding 3HB-CoA synthase and/or the PhaG gene ofrecombinant R. eutropha may be performed by following a conventionalmethod mentioned in the prior art. For example, the method may includepreparation of a vector containing the gene encoding the enzyme thatconverts lactate to lactyl-CoA and/or the gene of PHA synthase that useslactyl-CoA as a substrate as well as transformation of R. eutropha inwhich a wild-type PHA synthesis operon is removed from the recombinantvector.

The term “vector” implies a DNA construct containing a DNA sequenceoperably linked to a control sequence capable of expressing DNA in asuitable host. In the present invention, the vector may be a plasmidvector, bacteriophage vector, cosmid vector or Yeast ArtificialChromosome (YAC) vector, although a plasmid vector is typically used.For example, a typical plasmid vector used herein may have (a) areplication origin for effective replication into several hundreds ofplasmid vectors per host cell, (b) an antibiotic resistance gene for theselection of a host cell transformed by the plasmid vector, and (c) arestriction enzyme cutting site into which a foreign DNA fragment can beinserted. Although there is no suitable restriction enzyme cutting site,the vector may be easily ligated with foreign DNA using a syntheticoligonucleotide adaptor or linker following conventional methods.

As shown in the prior art, to increase the expression of a transformedgene, the corresponding gene should be operably linked to an expressioncontrol sequence that is involved in transcription and translation inthe selected expression host. Preferably, the expression controlsequence and corresponding gene are included in a single expressionvector containing both a bacterial selectable marker and replicationorigin. When the expression host is a eukaryotic cell, the expressionvector should further include a useful expression marker.

The term “expression control sequence” implies a DNA sequence that isessential for the expression of an operably linked coding sequence in aspecific host. The control sequence includes a promoter for initiatingtranscription, a random operator sequence for controlling transcription,a sequence for coding a suitable mRNA ribosome binding site (RBS), and asequence for controlling the termination of transcription andtranslation. For example, a control sequence suitable for a prokaryotecell includes a promoter, a random operator sequence, and an mRNA RBS. Acontrol sequence suitable for a eukaryotic cell includes a promoter, apolyadenylation signal, and an enhancer. The promoter is the mostcritical factor that affects the gene expression in a plasmid.Therefore, a high-expression promoter such as the SRα promoter orcytomegalovirus-derived promoter may be used.

To express a DNA sequence using the present invention, any one of thevarious expression control sequences may be employed in a vector.Examples of useful expression control sequences include the early andlate promoters of SV40 or adenovirus as well as lac system, trp system,TAC system, TRC system, T3 and T7 promoters, the major operator andpromoter regions of phage λ, the control region of the fD coat protein,the promoter of the 3-phosphoglycerate kinase gene or that of adifferent glycolytic enzyme, the promoters of phosphatase genes, e.g.,Pho5, a promoter of the yeast α-mating system, and other sequences withconfigurations or derivations known to control the expression ofprokaryotic and eukaryotic cells or their viruses, and variouscombinations thereof.

Nucleic acid becomes “operably linked” to a nucleotide sequence whenboth are in a functional relationship. An appropriate molecule (e.g., atranscription-activating protein) may be the product of a gene andcontrol sequence(s) that became linked in such a manner that enablesgene expression. For example, the DNA encoding a pre-sequence orsecretory leader is operably linked to the DNA encoding a polypeptidewhen expressed as a pre-protein that participates in the secretion ofsaid polypeptide; a promoter or enhancer that affects the transcriptionof a coding sequence is operably linked to said coding sequence; and anRBS that affects the transcription or translation of a coding sequenceis operably linked to said coding sequence. In general, “operablylinked” implies that DNA sequences that are linked together arecontiguous. Specifically, regarding the secretory leader, “operablylinked” implies that DNA sequences are contiguous and in reading frame.However, an enhancer in contact with the coding sequence is notrequired. Linkage between sequences may be performed by ligation at aconvenient restriction enzyme site. However, a synthetic oligonucleotideadaptor or linker may be used according to conventional methods whenthere is no restriction enzyme site.

It should be noted that not all vectors and expression control sequencesdo function equally in the expression of DNA sequences according to thepresent invention. Similarly, all hosts do not function equally in thesame expression system. However, those of ordinary skill in the art maybe able to select various vectors, expression control sequences, andhosts without deviating from the scope of the present invention orincreasing experimental error. For example, a vector must be selected byconsidering the host. In addition, on should consider the number ofcopies of the vector, the ability to control the number of copies, andthe expression of other proteins encoded by the corresponding vector,such as an antibiotic marker. Considering these variables, those ofordinary skill in the art may be able to determine suitable combinationsof vectors, expression control sequences and hosts.

The present invention also provides a method for preparation ofpolylactate or a hydrolxyalkanoate-lactate copolymer, culture of arecombinant R. eutropha in medium containing a carbon source andlactate, or a carbon source, lactate and hydroxyalkanoate, and recoveryof polylactate or hydroxyalkanoate-lactate copolymer from recombinant R.eutropha.

For example, when cultured in glucose-containing medium or mediumcontaining glucose and hydroxyalkanoate, recombinant R. eutropha willproduce either polylactate or a hydroxyalkanoate-lactate copolymer,respectively. However, when recombinant R. eutropha expresses a geneencoding 3HB-CoA synthase, hydroxyalkanoate-lactate copolymer can beprepared with a high molar fraction of hydroxyalkanoate, even when themedium is deficient in hydroxyalkanoate. When recombinant R. eutrophaexpresses PhaG, a hydroxyalkanoate-lactate copolymer of MCL can beprepared.

The hydroxyalkanoate-lactate copolymer may include, but is not limitedto, poly(3HA-co-LA), poly(3HB-co-LA), poly (3HP-co-LA),poly(3HB-co-4HB-co-LA), poly(3HP-co-4HB-co-LA), poly(3HB-co-3HV-co-LA),poly(4HB-co-LA-co-3HP), and poly(MCL 3-HA-co-LA).

Specifically, the yield of hydroxyalkanoate-lactate copolymer may varyaccording to the type of hydroxyalkanoate contained in the medium.

According to the present invention, the hydroxyalkanoate substrate forthe synthesis of hydroxyalkanoate-lactate copolymer may be at least oneof the following compounds: 3-hydroxybutyrate, 3-hydroxyvalerate,4-hydroxybutyrate, medium-chain-length (D)-3-hydroxycarboxylic acid with6 to 14 carbon atoms, 2-hydroxypropionic acid, 3-hydroxypropionic acid,3-hydroxyhexanoic acid, 3-hydroxyheptanoic acid, 3-hydroxyoctanoic acid,3-hydroxynonanoic acid, 3-hydroxydecanoic acid, 3-hydroxyundecanoicacid, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid,3-hydroxyhexadecanoic acid, 4-hydroxyvaleric acid, 4-hydroxyhexanoicacid, 4-hydroxyheptanoic acid, 4-hydroxyoctanoic acid, 4-hydroxydecanoicacid, 5-hydroxyvaleric acid, 5-hydroxyhexanoic acid, 6-hydroxydodecanoicacid, 3-hydroxy-pentenoic acid, 3-hydroxy-4-trans-hexenoic acid,3-hydroxy-4-cis-hexenoic acid, 3-hydroxy-5-hexenoic acid,3-hydroxy-6-trans-octenoic acid, 3-hydroxy-6-cis-octenoic acid,3-hydroxy-7-octenoic acid, 3-hydroxy-8-nonenoic acid,3-hydroxy-9-decenoic acid, 3-hydroxy-5-cis-dodecenoic acid,3-hydroxy-6-cis dodecenoic acid, 3-hydroxy-5-cis tetradecenoic acid,3-hydroxy-7-cis tetradecenoic acid, 3-hydroxy-5,8-cis-cis tetradecenoicacid, 3-hydroxy-4-methylvaleric acid, 3-hydroxy-4-methylhexanoic acid,3-hydroxy-5-methylhexanoic acid, 3-hydroxy-6-methylheptanoic acid,3-hydroxy-4-methyloctanoic acid, 3-hydroxy-5-methyloctanoic acid,3-hydroxy-6-methyloctanoic acid, 3-hydroxy-7-methyloctanoic acid,3-hydroxy-6-methylnonanoic acid, 3-hydroxy-7-methylnonanoic acid,3-hydroxy-8-methylnonanoic acid, 3-hydroxy-7-methyldecanoic acid,3-hydroxy-9-methyldecanoic acid, 3-hydroxy-7-methyl-6-octenoic acid,malic acid, 3-hydroxysuccinic acid-methyl ester, 3-hydroxyadipinicacid-methyl ester, 3-hydroxysuberic acid-methyl ester, 3-hydroxyazelaicacid-methyl ester, 3-hydroxysebacic acid-methyl ester, 3-hydroxysubericacid-ethyl ester, 3-hydroxysebacic acid-ethyl ester, 3-hydroxypimelicacid-propyl ester, 3-hydroxysebacic acid-benzyl ester,3-hydroxy-8-acetoxyoctanoic acid, 3-hydroxy-9-acetoxynonanoic acid,phenoxy-3-hydroxybutyric acid, phenoxy-3-hydroxyvaleric acid,phenoxy-3-hydroxyheptanoic acid, phenoxy-3-hydroxyoctanoic acid,para-cyanophenoxy-3-hydroxybutyric acid,para-cyanophenoxy-3-hydroxyvaleric acid,para-cyanophenoxy-3-hydroxyhexanoic acid,para-nitrophenoxy-3-hydroxyhexanoic acid, 3-hydroxy-5-phenylvalericacid, 3-hydroxy-5-cyclohexylbutyric acid, 3,12-dihydroxydodecanoic acid,3,8-dihydroxy-5-cis-tetradecenoic acid, 3-hydroxy-4,5-epoxydecanoicacid, 3-hydroxy-6,7-epoxydodecanoic acid,3-hydroxy-8,9-epoxy-5,6-cis-tetradecanoic acid,7-cyano-3-hydroxyheptanoic acid, 9-cyano-3-hydroxynonanoic acid,3-hydroxy-7-fluoroheptanoic acid, 3-hydroxy-9-fluorononanoic acid,3-hydroxy-6-chlorohexanoic acid, 3-hydroxy-8-chlorooctanoic acid,3-hydroxy-6-bromohexanoic acid, 3-hydroxy-8-bromooctanoic acid,3-hydroxy-11-bromoundecanoic acid, 3-hydroxy-2-butenoic acid,6-hydroxy-3-dodecenoic acid, 3-hydroxy-2-methylbutyric acid,3-hydroxy-2-methylvaleric acid, and 3-hydroxy-2,6-dimethylheptenoicacid.

The present invention provides a novel method for the preparation ofpolylactate or hydroxyalkanoate-lactate copolymer using a recombinantstrain of Ralstonia eutropha.

Exemplary embodiments of the present invention have been disclosedherein. Although specific terms are employed, they are to be interpretedonly in a generic and descriptive sense and not for the purpose oflimitation. Accordingly, it should be understood by those of ordinaryskill in the art that various changes in form and detail are possiblewithout deviating from the spirit and scope of the present invention asset forth in the following claims.

EXAMPLES <Example 1> Preparation of R. Eutropha Having Lost PHAProduction Capability

To remove the PHA biosynthesis gene operon involved in the synthesis ofpoly(3-hydroxybutyrate)[P(3HB)] in Ralstonia eutropha (R. eutropha), arecombinant vector was prepared as follows.

A DNA fragment containing the PHB-producing operon derived from R.eutropha H16 was cleaved from the pSYL105 vector (Lee et al., Biotech.Bioeng., 1994, 44:1337-1347) by BamHI/EcoRI and inserted into theBamHI/EcoRI recognition site of pBluescript II (Stratagene), therebyproducing pReCAB recombinant vector.

PHA synthase (phaC_(RE)) along with monomer-supplying enzymes (phaA_(RE)& phaB_(RE)) were constantly expressed in a pReCAB vector under the PHBoperon promoter. It is known that this vector also effectively operatesin E. coli (Lee et al., Biotech. Bioeng., 1994, 44:1337-1347). The newpReCAB vector was cleaved with BstBI/NdeI to remove the genes encodingR. eutropha H16 PHA synthase (phaC_(RE)), b-ketothiolase (phaA_(RE)) andacetoacetyl-CoA reductase (phaB_(RE)). A GFP gene amplified from a pEGFPplasmid (BD Biosciences Clontech) by PCR was then inserted into thevector (pΔCAB-GFP).

EGFP_F_BstBI aaaaattcgaaac aggaaacagaat atggtgagcaag (SEQ ID NO: 3)

EGFP_R_NdeI ggaattcCATATGttacttgtacagctcgtcca (SEQ ID NO: 4)

The pΔCAB-GFP vector was next cleaved with BamHI/XhoI, thereby producinga gene segment to which the R. eutropha PHA biosythesis promoter wasattached in the 5′ direction and to which a transcription terminatorgene was attached in the 3′ direction. The gene segment was insertedinto a pK18mobSacB vector (Schafer et al. Gene (1994) 145: 69-73)cleaved with BamHI/SalI, thereby producing the pK18-ΔCAB-GFP vector.Since the pK18mobSacB vector can express sacB, a recombinantmicroorganism was prepared by inserting a foreign gene into thechromosome using sucrose.

After the pK18-ΔCAB-GFP vector was transformed to E. coli S17-1, theS17-1 (pK18-ΔCAB-GFP) was cultured in an LB liquid medium containing 25mg/l kanamycin at 37° C. for 24 hours. R. eutropha NCIMB11599 was alsocultured in an LB liquid medium at 30° C. for 24 hours. These culturesolutions were mixed with each other to have a volume ratio of the S17-1(pK18-ΔCAB-GFP) to the R. eutropha NCIMB11599 of 3:1, and added drop bydrop to an LB solid medium by 100 ul. The resulting plate was culturedin a static incubator at 30° C. for 18 hours. During the culture, matingoccurred, in which the pK18-ΔCAB-GFP vector of the S17-1 was transferredto Ralstonia eutropha, resulting in, as shown in FIG. 3, a firstcrossover at a homology site of chromosomal DNA of Ralstonia. Since thepK18-ΔCAB-GFP is impossible to be replicated in R. eutropha, when thepK18-ΔCAB-GFP was normally inserted into the chromosome of R. eutrophathrough the first crossover between genes, R. eutropha showed resistanceto the plate containing 500 mg/L kanamycin.

A colony in which the pK18-ΔCAB-GFP was inserted into the chromosome ofR. eutropha through the first crossover was selected by suspending thecells mated in the LB plate in an LB liquid medium, and plating thesuspension on a plate containing 500 mg/L kanamycin and 35 mg/lchloramphenicol. For a second crossover, the recombinant R. eutropha inwhich the first crossover was done was cultured in an LB liquid mediumat 30° C. for 24 hours, and then 100 ul of the culture solution wasplated on an LB plate containing 70 g/L sucrose. R. eutropha in whichthe second crossover occurred by a sacB gene was selected as recombinantR. eutropha through PCR (see FIG. 3). After the second crossover wasnormally done, the recombinant R. eutropha lost the PHA biosynthesisoperon (phaCAB), but the GFP gene remained in the chromosome. Throughcolony PCR, the recombinant R. eutropha in which the GFP was normallyinserted into the chromosome was found, and was called as R. eutrophaGFP.

<Example 2> Preparation of Recombinant R. eutropha into which PHASynthase from Pseudomonas sp. 6-19 (KCTC 11027BP) and Propionyl-CoATransferase (CPPCT) from Clostridium propionicum are Inserted

The pK18-ΔCAB-GFP vector prepared in Example 1 was cleaved withBamHI/NdeI to remove GFP, and a gene segment obtained by cleaving apPs619C1335CPPCT540 vector with BamHI/NdeI was inserted thereinto,thereby preparing a pK18-ΔCAB-335540 vector. By using the vector, arecombinant R. eutropha 335540, in which phaCAB was removed andphaC1_(Ps6-19)335 from Pseudomonas sp. 6-19 (KCTC 11027BP) andpropionyl-CoA transferase (CPPCT540) from Clostridium propionicum wereinserted into a chromosome, was prepared (see Table 1). The preparingprocess was performed in the same manners as Example 1 using E. coliS17-1 (see FIG. 3).

TABLE 1 Recombinant R. eutropha Recombinant plasmid used herein R.eutropha NCIMB11599 R. eutropha GFP pK18-ΔCAB-GFP R. eutropha 335540pK18-ΔCAB-335540 R. eutropha 335ReAB pK18-ΔCAB-335ReAB R. eutropha310540ReAB pK18-ΔCAB-310540ReAB R. eutropha 312540ReABpK18-ΔCAB-312540ReAB

<Example 3> Preparation of Recombinant R. eutropha into which PHASynthase from Pseudomonas sp. 6-19 (KCTC 11027BP) and Ketothiolase(phaA_(RE)) and Acetoacetyl-CoA Reductase (phaB_(RE)) from R. eutrophaH16 are Inserted

The pK18-ΔCAB-GFP vector prepared in Example 1 was cleaved withBamHI/NdeI to remove GFP, and a gene segment obtained by cleavingpPs619C1335ReAB vector with BamHI/NdeI was inserted thereinto, therebypreparing pK18-ΔCAB-335ReAB vector. By using the vector, a recombinantR. eutropha 335ReAB, in which phaCAB was removed and phaC1_(Ps6-19)335from Pseudomonas sp. 6-19 (KCTC 11027BP) and PHB monomer-supplyingenzymes (phaA_(RE) & phaB_(RE)) from R. eutropha H16 were inserted intoa chromosome, was prepared (see Table 1). The preparing process wasperformed in the same manners as Example 1 using E. coli S17-1 (see FIG.3).

<Example 4> Preparation of Recombinant R. eutropha into which PHASynthase from Pseudomonas sp. 6-19 (KCTC 11027BP), Propionyl-CoATransferase (CPPCT) from Clostridium propionicum, and Ketothiolase(phaA_(RE)) and Acetoacetyl-CoA Reductase (phaB_(RE)) from R. eutrophaH16 are Inserted

The pK18-ΔCAB-GFP vector prepared in Example 1 was cleaved withBamHI/NdeI to remove GFP, and gene segments obtained by cleavingpPs619C1310CPPCT540ReAB and pPs619C1312CPPCT540ReAB vectors withBamHI/NdeI were inserted thereinto, thereby preparingpK18-ΔCAB-310540ReAB and pK18-ΔCAB-312540ReAB vectors, respectively. Byusing these vectors, recombinant R. eutropha 310540ReAB and R. eutropha312540ReABphaCAB, in which phaCAB was removed and phaC1_(Ps6-19)310 orphaC1_(Ps6-19)312 from Pseudomonas sp. 6-19 (KCTC 11027BP),propionyl-CoA transferase(CPPCT540) from Clostridium propionicum, andPHB monomer-supplying enzymes (phaA_(RE) & phaB_(RE)) from R. eutrophaH16 were inserted into a chromosome, were prepared (see Table 1). Thepreparing process was performed in the same manners as Example 1 usingE. coli 517-1 (see FIG. 3).

<Example 5> Biosynthesis of P (3HB-Co-LA) Copolymer Through Culture ofRecombinant R. eutropha

The recombinant R. eutropha shown in Table 1 was cultured in a minimalmedium containing glucose as a basic substrate and 34 ug/mLchloramphenicol, resulting in biosynthesis of a P(3HB-co-LA) copolymer.The composition of the minimal medium was as follows (per L; KH₂PO₄,2.65 g; Na₂HPO₄, 3.8 g; NH₄Cl, 0.72 g; MgSO₄7H₂O, 0.4 g; Tracer, 1 mL).In addition, the composition of tracers was as follows (per L;FeSO₄.7H₂O, 10 g; ZnSO₄.7H₂O, 2.25 g; CuSO₄.5H₂O, 1 g; MnSO₄.5H₂O, 0.5g; CaCl₂.2H₂O, 2 g; Na₂B₄O₇.7H₂O, 0.23 g; (NH₄)₆Mo₇O₂₄, 0.1 g; 35% HCl,10 mL). Prior to a main culture, a seed culture was performed in an LBmedium containing antibiotics for 30 hours. The seed-culture solutionwas inoculated to the minimal medium containing a substrate andantibiotics to have a concentration of 1% for the main culture for 4days. All cultures were performed at 30° C. at a speed of 200 rpm. Afterthe culture was completed, a cell lysate was harvested bycentrifugation. The harvested cell lysate was dried in a drier at 80° C.for 48 hours, and analyzed by gas chromatography to measure the contentof the P(3HB-co-LA) copolymer accumulated in the cell lysate. The resultis shown in Table 2. Reference materials used in the analysis wereP(3HB-co-12 mol % 3HV) copolymer and PLA polymer.

TABLE 2 Biosynthesis of P(3HB-co-LA) copolymer through culture ofrecombinant R. eutropha Recombinant P(3HB-co-LA) LA R. eutrophaSubstrate (wt %) mol % R. eutropha 2% glucose 24.33 0.00 335540 2%glucose, 3HB* 47.73 0.00 2% glucose, NaL⁺ 7.72 31.71 2% glucose, 3HB,NaL⁺ 25.20 16.18 R. eutropha 2% glucose 46.33 0.05 310540ReAB 1.5%glucose, NaL⁺⁺ 24.06 8.64 R. eutropha 2% glucose 46.50 0.06 312540ReAB1.5% glucose, NaL⁺⁺ 12.87 7.18 Nal⁺⁺⁺ 17.97 *3HB: 3-hydroxybutyrate, 2g/L ⁺NaL: Sodium lactate (pH 7), 4 g/L ⁺⁺NaL: Sodium lactate (pH 7), 6g/L ⁺⁺⁺NaL: Sodium lactate (pH 7), 24 g/L

<Example 6> Biosynthesis of P(3HB-Co-LA-Co-mcl3HA) Copolymer ThroughCulture of Recombinant R. eutropha

The R. eutropha GFP was transformed to a vector expressing PHA synthasefrom Pseudomonas sp. 6-19 (KCTC 11027BP), propionyl-CoA transferase(CPPCT) from Clostridium propionicum, and PhaG from P. putida KT2440,and then cultured as described in Example 5. As a carbon source, 2%glucose was used. The content of a copolymer accumulated in a celllysate is shown in Table 3.

A process of preparing a vector was as follows.

To begin with, a phaG gene amplified from P. putida KT2440 by PCR wasinserted into an NdeI site of a pPs619C1300CPPCT532 orpPs619C1334CPPCT532 vector (pPs619C1300CPPCT532PhaG orpPs619C1334CPPCT532PhaG). Subsequently, the pPs619C1300CPPCT532PhaG orpPs619C1334CPPCT532PhaG was cleaved with BamHI/XhoI, a gene segmentobtained thereby was inserted into the same site of pBBR1MCS2 vector,thereby preparing a recombinant plasmid replicable in R. eutropha(pMCS2Ps619C1300CPPCT532PhaG or pMCS2Ps619C1334CPPCT532PhaG). By usingthe vector, a recombinant R. eutropha was prepared.

KTPhaG500f-NdeI (SEQ ID NO: 5) ggaattc catatg ggggttggcgccggg ggagKTPhaGb-2100-NdeI (SEQ ID NO: 6)5- ggaattc catatg gga tcg gtg ggt aat tgg cc

TABLE 3 Biosynthesis of P(LA-co-3HB-co-mcl3HA) copolymer through cultureof recombinant R. eutropha PHA PHA composition (mol %) Enzymes incontent LA 3HB 3HHx 3HO 3HD 3HDD 3H5DD Plasmid (wt %) (C3) (C4) (C6)(C8) (C10) (C12) (C12′) PhaC1-300_(Ps6-19) 20.9 2.0 94.1 0.5 0.8 0.9 1.50.3 Pct532 PhaG PhaC1-334_(Ps6-19) 19.7 2.7 91.7 0.5 1.2 1.3 2.3 0.3Pct532 PhaG

The invention claimed is:
 1. A recombinant Ralstonia eutropha (R.eutropha) capable of producing polylactate or a hydroxyalkanoate-lactatecopolymer, wherein polyhydroxyalkanoate (PHA) biosynthesis gene operonof a wild-type R. eutropha is removed, and a gene of an enzymeconverting lactate into lactyl-CoA and a gene of a PHA synthase usinglactyl-CoA as a substrate are introduced, wherein the gene of the enzymeconverting lactate into lactyl-CoA is a propionyl-CoA transferase (pct)gene, wherein the pct gene has a nucleotide sequence (cppct537) of SEQID NO: 1 comprising the T669C, A1125G, and T1158C mutations whosecorresponding amino acid sequence comprises the Thr199Ile mutation. 2.The recombinant R. eutropha according to claim 1, wherein the pct geneis derived from Clostridium propionicum.
 3. The recombinant R. eutrophaaccording to claim 1, wherein the gene of the PHA synthase usinglactyl-CoA as a substrate is derived from Pseudomonas sp. 6-19.
 4. Therecombinant R. eutropha according to claim 1, wherein the gene of thePHA synthase using lactyl-CoA as a substrate has a nucleotide sequencecorresponding to the amino acid sequence of SEQ ID NO: 2 or the aminoacid sequence of SEQ ID NO: 2 with at least one of the followingmutations: E130D, S325T, L412M, S477R, S477H, S477F, S477Y, S477G,Q481M, Q481K and Q481R.
 5. The recombinant R. eutropha according toclaim 4, wherein the gene of the PHA synthase using lactyl-CoA as asubstrate has a nucleotide sequence corresponding to at least one aminoacid sequence selected from the group consisting of: the amino acidsequence (C1335) of SEQ ID NO: 2 containing the E130D, S325T, L412M,S477G and Q481M mutations; the amino acid sequence (C1310) of SEQ ID NO:2 containing the E130D, S477F and Q481K mutations; and the amino acidsequence (C1312) of SEQ ID NO: 2 containing the E130D, S477F and Q481Rmutations.
 6. The recombinant R. eutropha according to claim 1, furthercomprising a gene coding a 3HB-CoA synthase.
 7. The recombinant R.eutropha according to claim 6, wherein the gene coding the 3HB-CoAsynthase includes a ketothiolase gene and an acetoacetyl-CoA reductasegene.
 8. The recombinant R. eutropha according to claim 7, wherein theketothiolase gene and the acetoacetyl-CoA reductase gene are derivedfrom the R. eutropha.
 9. The recombinant R. eutropha according to claim1, which is capable of producing a hydroxyalkanoate-lactate copolymer ofMedium Chain Length (MCL).
 10. The recombinant R. eutropha according toclaim 1, further comprising a PhaG gene.
 11. The recombinant R. eutrophaaccording to claim 10, wherein the PhaG gene is derived from P. PutidaKT2440.
 12. A method of preparing polylactate or ahydroxyalkanoate-lactate copolymer, comprising: culturing a recombinantRalstonia eutropha of claim 1 in a medium containing a carbon source andlactate, or a carbon source, lactate and hydroxyalkanoate; andrecovering polylactate or a hydroxyalkanoate-lactate copolymer from therecombinant R. eutropha.
 13. The method according to claim 12, whereinhydroxyalkanoate of the hydroxyalkanoate-lactate copolymer includes atleast one selected from the group consisting of 3-hydroxybutyrate,3-hydroxyvalerate, 4-hydroxybutyrate, medium-chain-length(D)-3-hydroxycarboxylic acid with 6 to 14 carbon atoms,2-hydroxypropionic acid, 3-hydroxypropionic acid, 3-hydroxyhexanoicacid, 3-hydroxyheptanoic acid, 3-hydroxyoctanoic acid, 3-hydroxynonanoicacid, 3-hydroxydecanoic acid, 3-hydroxyundecanoic acid,3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid,3-hydroxyhexadecanoic acid, 4-hydroxyvaleric acid, 4-hydroxyhexanoicacid, 4-hydroxyheptanoic acid, 4-hydroxyoctanoic acid, 4-hydroxydecanoicacid, 5-hydroxyvaleric acid, 5-hydroxyhexanoic acid, 6-hydroxydodecanoicacid, 3-hydroxy-pentenoic acid, 3-hydroxy-4-trans-hexenoic acid,3-hydroxy-4-cis-hexenoic acid, 3-hydroxy-5-hexenoic acid,3-hydroxy-6-trans-octenoic acid, 3-hydroxy-6-cis-octenoic acid,3-hydroxy-7-octenoic acid, 3-hydroxy-8-nonenoic acid,3-hydroxy-9-decenoic acid, 3-hydroxy-5-cis-dodecenoic acid,3-hydroxy-6-cis dodecenoic acid, 3-hydroxy-5-cis tetradecenoic acid,3-hydroxy-7-cis tetradecenoic acid, 3-hydroxy-5,8-cis-cis tetradecenoicacid, 3-hydroxy-4-methylvaleric acid, 3-hydroxy-4-methylhexanoic acid,3-hydroxy-5-methylhexanoic acid, 3-hydroxy-6-methylheptanoic acid,3-hydroxy-4-methyloctanoic acid, 3-hydroxy-5-methyloctanoic acid,3-hydroxy-6-methyloctanoic acid, 3-hydroxy-7-methyloctanoic acid,3-hydroxy-6-methylnonanoic acid, 3-hydroxy-7-methylnonanoic acid,3-hydroxy-8-methylnonanoic acid, 3-hydroxy-7-methyldecanoic acid,3-hydroxy-9-methyldecanoic acid, 3-hydroxy-7-methyl-6-octenoic acid,malic acid, 3-hydroxysuccinic acid-methyl ester, 3-hydroxyadipinicacid-methyl ester, 3-hydroxysuberic acid-methyl ester, 3-hydroxyazelaicacid-methyl ester, 3-hydroxysebacic acid-methyl ester, 3-hydroxysubericacid-ethyl ester, 3-hydroxysebacic acid-ethyl ester, 3-hydroxypimelicacid-propyl ester, 3-hydroxysebacic acid-benzyl ester,3-hydroxy-8-acetoxyoctanoic acid, 3-hydroxy-9-acetoxynonanoic acid,phenoxy-3-hydroxybutyric acid, phenoxy-3-hydroxyvaleric acid,phenoxy-3-hydroxyheptanoic acid, phenoxy-3-hydroxyoctanoic acid,para-cyanophenoxy-3-hydroxybutyric acid,para-cyanophenoxy-3-hydroxyvaleric acid,para-cyanophenoxy-3-hydroxyhexanoic acid,para-nitrophenoxy-3-hydroxyhexanoic acid, 3-hydroxy-5-phenylvalericacid, 3-hydroxy-5-cyclohexylbutyric acid, 3,12-dihydroxydodecanoic acid,3,8-dihydroxy-5-cis-tetradecenoic acid, 3-hydroxy-4,5-epoxydecanoicacid, 3-hydroxy-6,7-epoxydodecanoic acid,3-hydroxy-8,9-epoxy-5,6-cis-tetradecanoic acid,7-cyano-3-hydroxyheptanoic acid, 9-cyano-3-hydroxynonanoic acid,3-hydroxy-7-fluoroheptanoic acid, 3-hydroxy-9-fluorononanoic acid,3-hydroxy-6-chlorohexanoic acid, 3-hydroxy-8-chlorooctanoic acid,3-hydroxy-6-bromohexanoic acid, 3-hydroxy-8-bromooctanoic acid,3-hydroxy-11-bromoundecanoic acid, 3-hydroxy-2-butenoic acid,6-hydroxy-3-dodecenoic acid, 3-hydroxy-2-methylbutyric acid,3-hydroxy-2-methylvaleric acid, and 3-hydroxy-2,6-dimethylheptenoicacid.